浙江医药:获得XC2309注射液《药物临床试验批准通知书》
Group 1 - Zhejiang Medicine Co., Ltd. received approval from the National Medical Products Administration for the clinical trial of XC2309 injection [2] - The company's revenue composition for the year 2024 is as follows: human nutritional products account for 50.1%, pharmaceuticals account for 48.85%, other businesses account for 0.64%, and additional services account for 0.41% [2]